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ABSTRACT
Cardiogenesis requires proper speciﬁcation, proliferation, and differentiation of cardiac progenitor cells (CPCs). The differentiation of CPCs to
speciﬁc cardiac cell types is likely guided by a comprehensive network comprised of cardiac transcription factors and epigenetic complexes. In
this review, we describe how the ATP‐dependent chromatin remodeling SWI/SNF complexes work synergistically with transcription and
epigenetic factors to direct speciﬁc cardiac gene expression during CPC differentiation. Furthermore, we discuss how SWI/SNF may prime
chromatin for cardiac gene expression at a genome‐wide level. A detailed understanding of SWI/SNF‐mediated CPC differentiation will
provide important insight into the etiology of cardica defects and help design novel therapies for heart disease. J. Cell. Biochem. 114: 2437–2445,
2013.  2013 Wiley Periodicals, Inc.
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Heart disease remains the leading cause of death worldwideand presents a major economic burden to society. Congenital
heart diseases (CHDs) are among the most common and most
devastating birth defects in humans, affecting about 1% of live births
(American Heart Association). Despite great progress in cardiac
research, we have only limited knowledge on the etiology of CHDs
and we still lack effective treatment for most of these patients.
Meanwhile, myocardial infarction, commonly known as heart attack,
results in permanent heart muscle damage or death, and is the number
one killer of heart patients. Patients who survive a heart attack often
develop heart failure symptoms and almost half of the affected
patients die within 1 year from the onset of symptoms [Jessup
and Brozena, 2003; Lopez et al., 2006]. Naturally, it is critical to
understand the etiology of CHDs, and there is a high demand for
developing novel therapeutic strategies to treat CHDs and heart
failure.
The recent identiﬁcation, characterization, and isolation of CPCs
has provided new opportunities for understanding the etiology of
CHDs and developing cell‐based regenerative therapies for both CHDs
and heart failure [Moretti et al., 2006;Wu et al., 2006; Bu et al., 2009].
The early CPCs are originated from lateral plate mesoderm soon after
gastrulation. At E7.75 in mice, these CPCs formed cardiac crescent
which is further classiﬁed into the ﬁrst heart ﬁeld (FHF) and the
second heart ﬁeld (SHF). CPCs from FHF and SHF then differentiated
into cardiomyocyte and endocardial cells to form the linear heart tube
at later stages. After a complex morphogenetic event and cell
differentiation and maturation process, these CPCs formed the four
chamber heart [Srivastava, 2006]. CPCs or CPC‐like cells have also
been identiﬁed in cardiac neural crest, epicardium, sinus venosus, as
well as in adult heart [Beltrami et al., 2003; Cai et al., 2003; Oh
et al., 2003; Kattman et al., 2006; Moretti et al., 2006; Wu et al., 2006;
Yang et al., 2008; Blin et al., 2010].
The isolation and characterization of embryonic CPCs provides a
new paradigm for studying CHDs. CHDs could be regarded as CPC
diseases, that is, defects of CPCs in their speciﬁcation, proliferation,
migration, and differentiation likely lead to CHDs. In support of this
notion, many transcription factors and signaling pathways that are
essential for early cardiogenesis are also involved in CPC develop-
ment and dysfunction of these factors and pathways is often
associated with inherited CHDs [Keegan et al., 2005; Black, 2007;
Bruneau, 2008; Kwon et al., 2009; Stevens et al., 2010]. Therefore,
understanding the mechanisms of CPC development will shed new
light on the etiology of CHDs. In particular, an ESC‐based CPC
speciﬁcation, proliferation, and differentiation system combinedwith
lineage tracing will be an attractive in vitro model system to study
CHDs (Fig. 1) [Martin‐Puig et al., 2008; Hansson et al., 2009].
CPCs are also ideal candidate cells for cell‐based cardiac
regenerative therapies to repair defective or damaged hearts through
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guided differentiation. CPCs derived from FHF and SHF are
multipotent and capable of differentiating into cardiomyocytes,
smooth muscle cells, and endothelial cells [Moretti et al., 2006; Wu
et al., 2006; Bu et al., 2009], strongly suggesting that these cells are
promising candidates in cell‐based heart therapy. Due to their
commitment to cardiac lineages, it is less likely that these cells will
form teratomas or other unwanted cell types when injected into
patient hearts. Numerous studies have shown that injecting CPCs into
infarcted animal hearts improves the heart function [Blin et al., 2010;
Christoforou et al., 2010]. However, it appears that the engrafted CPCs
differentiated predominantly into early cardiomyocytes and the long‐
term effect needs to be further investigated. It is also conceivable that
amore balanced differentiation of these CPCs into smoothmuscle and
endothelial cells to restore the coronary vasculature in the infarcted
area may have a better therapeutic effect.
Therefore, to realize the full potential of CPCs in cardiac
regenerative medicine, it is critical to understand the molecular
mechanisms guiding directed differentiation of CPCs into desired
mature cell types in the heart. Currently we have only limited
knowledge about the CPC differentiation mechanisms which
represents a roadblock in cell‐based heart therapies for both CHDs
and heart failure (Fig. 1).
MOLECULAR MECHANISMS GUIDING CPC
DIFFERENTIATION
Though cardiogenesis has been extensively studied, the isolation and
characterization of embryonic CPCs have only been accomplished in
recent years and how these CPCs are programmed to differentiate into
different cardiac lineages is largely unknown. It is very likely that the
same transcription networks identiﬁed in cardiogenesis will function
similarly in CPC proliferation, migration, and differentiation [Olson,
2006; Srivastava, 2006; Wu et al., 2008]. Furthermore, it has become
increasingly clear that epigenetic regulation is also essential for
gene regulation during development and on set of diseases [Zaidi
et al., 2011]. There are three major types of chromatin modiﬁcations
that play a key role in epigenetic regulation: DNA methylation,
histone modiﬁcation, and ATP‐dependent chromatin remodeling
[Suzuki and Bird, 2008; Ho and Crabtree, 2010; Zhou et al., 2011].
These chromatin modiﬁcations are catalyzed by a large number of
protein complexes. One key group of the ATP‐dependent chromatin
remodeling suprerfamily is the SWI/SNF subfamily (Fig. 2A) [de la
Serna et al., 2006; Wu et al., 2009]. To date, we have very limited
knowledge about epigenetic regulation during cardiogenesis and
CPC differentiation.
A comparison of epigenetic modiﬁcations between ESCs and CPCs
may provide useful insights into the epigenetic mechanisms of
CPC differentiation. In ESCs, epigenetic modiﬁers and chromatin
signatures play a key role in pluripotency and differentiation. Studies
have revealed that two classes of genes in ESCs may determine
pluripotency and differentiation: active and “poised” genes [Mik-
kelsen et al., 2007; Rada‐Iglesias et al., 2011]. Active genes include
those master genes essential for ESC pluripotency and self‐renewal.
Many poised genes encode developmentally important factors whose
expression is temporally silenced in ESCs but is readily activated
during ESC differentiation. Both classes aremarked by the presence of
chromatin regulators p300 and BRG1 (catalytic subunit of SWI/SNF),
monomethylation of histone H3 at lysine 4 (H3K4me1), and low
nucleosomal density. These two classes are also marked by the
enrichment of histone H3 lysine 4 trimethylation (H3K4me3), but they
can be distinguished by the acetylation of histone H3 at lysine 27
(H3K27ac) in active genes, and the absence of H3K27ac and
Fig. 1. A working model of heart cell lineage diversiﬁcation frommultipotent mesodermal progenitors. CPCs, cardiac progenitor cells; EPDCs, endothelial progenitor‐derived cells;
FHF, ﬁrst heart ﬁeld; PEO, proepicardial organ; SHF, second heart ﬁeld. The molecular mechanisms guiding the proper differentiation of the cardiac lineages are poorly deﬁned.
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enrichment of histone H3 lysine 27 trimethylation (H3K27me3)
in poised genes [Mikkelsen et al., 2007; Creyghton et al., 2010;
Rada‐Iglesias et al., 2011].
It is likely that similar epigenetic factors and chromatin signatures
are present in key genes in CPCs and are critical for the differentiation
of CPCs into various lineages. Indeed, two studies have shown that
during differentiation of embryonic stem cells to cardiovascular cells,
distinct histone modiﬁcations are associated with key regulators of
cardiogenesis, and this modiﬁcation patterns can be applied to
identify novel genes essential for cardiac development [Paige
et al., 2012; Wamstad et al., 2012]. These studies strongly suggest
that identifying the epigenetic factors and the chromatin signatures
of key cardiac genes in CPCs could be an essential step towards
elucidating the mechanisms of CPC differentiation. Remarkably, the
chromatin signatures that deﬁne the two classes of genes described
above are tightly associated with SWI/SNF (Fig. 2A), a major complex
that plays a key role in various aspects of development, including
heart development and disease.
SWI/SNF IN CARDIOGENESIS AND CPC
DIFFERENTIATION
The SWI/SNF complexes are the prototype of ATP‐dependent
chromatin remodeling machines that are evolutionarily conserved
Fig. 2. Composition and enzymatic activities of SWI/SNF. A: Composition of SWI/SNF complex. The SWI/SNF are composed of 10–12 subunits. Certain subunits are
interchangeable for tissue speciﬁc function. The assembles of each subunit in the ﬁgure do not represent their actual interaction. B: Working models of SWI/SNF‐mediated
chromatin remodeling. SWI/SNF use the energy of ATP hydrolysis to (1) move the nucleosomes along the DNA (upper left panel), (2) remodel nucleosomes and generate stable DNA
loops within nucleosomes and dinucleosome‐like species (upper right panel), (3) displace histones completely from the DNA (lower left panel), and (4) replace old histones with new
ones (lower right panel).
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from yeast to human. The major enzymatic function of the SWI/SNF
complexes is to remodel the nucleosome on DNA [Kingston and
Tamkun, 2007] (Fig. 2B). The SWI/SNF complexes can function in
several different ways: to move the nucleosomes along the DNA
(Fig. 2B, upper left panel); to remodel nucleosomes and generate
stable DNA loops within nucleosomes and dinucleosome‐like species
(Fig. 2B, upper right panel); to displace histones completely from the
DNA (Fig. 2B, lower left panel); and to replace old histones with
new ones by transferring the histone octamer to accepter DNA
and exchanging H2A/H2B dimers between nucleosomes [Lorch
et al., 1999; Whitehouse et al., 1999] (Fig. 2B, lower right panel). Even
though these identiﬁed actions of SWISNF have been basedmostly on
in vitro experiments or in vivo analyses using small artiﬁcial DNA
templates, these ﬁndings clearly suggest that SWI/SNF complexes
play a signiﬁcant role in regulating the chromatin plasticity required
for CPC differentiation.
Mammalian SWI/SNF complexes are able to form various
assemblies from different subunits [Cairns et al., 1996; Wang
et al., 1996; Nie et al., 2000; Xue et al., 2000; Yan et al., 2005]. A series
of studies show that SWI/SNF can be divided into two subfamilies.
One includes yeast SWI/SNF, ﬂy BAP, and mammalian BAF (SWI/
SNF‐A) complexes, the other includes yeast RSC, ﬂy PBAP, and
mammalian PBAF (SWI/SNF‐B) complexes. BAF and PBAF share
eight common subunits, and each has two unique ones. BAF250a
(Arid1a)‐ and BAF250b (Arid1b) are uniquely associated with BAF,
and BAF180 (Pb1) and BAF200 (Arid2) are uniquely associated with
PBAF (Fig. 2A).
Recent studies also show that the stoichiometry and subunit
composition of SWI/SNF are distinct in different cells and they
change dynamically during differentiation. For examples, ES cells
express a high level of BAF155, BAF250a, Brg1 but a low level of
BAF170 and Brm [Yan et al., 2008; Ho et al., 2009]. These cell type
speciﬁcity is also found in other developmental processes [Lickert
et al., 2004; Lessard et al., 2007; Lange et al., 2008; Ho et al., 2009].
Moreover, the SWI/SNF subunits could be encoded by several genes
to form a diversity of complexes which modulated different
developmental and cell differentiation processes. ATPase Brg1 or
Brm, with BAF170, BAF155, and BAF47 form the basis of the SWI/
SNF complex. The other subunits including BAF45, BAF53, BAF60,
BAF180, BAF200, BAF250, and actin, contain a set of variants to
form the speciﬁc SWI/SNF complexes (Fig. 2A) [Wang et al., 1996;
Wu et al., 2009].
Thus, it has been proposed that the SWI/SNF complex is uniquely
deployed in each tissue to guide tissue‐speciﬁc differentiation
programs with its speciﬁc subunit composition and stoichoimetry.
Indeed, it appears that there is a cardiac speciﬁc SWI/SNF complex
and its components have been shown to be essential for various stages
of cardiogenesis. We discuss the functions of these subunits in
cardiogenesis and CPC differentiation below.
BAF60C
BAF60c is a SWI/SNF component speciﬁcally expressed in heart and
somites. RNAi knockdown of BAF60c caused abnormal cardiac and
skeletal muscle development [Lickert et al., 2004]. The right ventricle
marker Hand2 is absent and the outﬂow tract is shortened in BAF60c
knockdown embryos suggesting that BAF60c plays a speciﬁc role in
SHF expansion. Furthermore, BAF60c can promote the interaction of
Brg1 with transcription factors such as Tbx5, Nkx2.5, and Gata4 in
vitro. Intrigueingly, BAF60c, working together with Tbx5 and Gata4,
could induce non‐myogenic mesoderm into cardiomyocytes ex vivo
[Takeuchi and Bruneau, 2009]. Moreover, Gata5 and BAF60c is able
to promoter myocardial differentiation by directing cells migration to
heart tube region [Lou et al., 2011]. Transplant assay in zebraﬁsh
showed that cardiac SWI/SNF can response to many key cardiogenic
signals such as Wnt, Bmp as well as FGF signals to promote efﬁcient
cardiomyocyte differentiation suggesting SWI/SNF could have
important roles in CPC formation. These results indicate that
BAF60c contributes to the cardiac speciﬁcity of SWI/SNF and
strongly suggest its potential key role in CPC differentiation.
BAF180
BAF180 is a unique polypeptide component of PBAF but not BAF. Our
studies indicate that BAF180 is required for cardiac morphogenesis
[Wang et al., 2004] and deletion of BAF180 in epicardial cells leads to
impaired epithelial‐to‐mesenchymal‐ transition (EMT) of epicardium
and causes failure of coronary vessel formation during embryonic
development [Huang et al., 2008]. BAF180 deletion affects the
a‐SMA expression and coronary vessel formation, suggesting that
BAF180 mediates the differentiation of endothelial progenitor‐
derived cells (EPDCs) into myoﬁbroblast, endothelial cells, and
smooth muscle cells. Although the mechanism of BAF180 in
regulating CPC differentiation is not clear, it should be noted that
BAF180/PBAF is required in retinoic acid (RA) signaling during heart
development, presumably by serving as a cofactor for RXRa, PPARg,
and other RA‐related nuclear receptors. Ablation of BAF180 in
mouse embryos results in severe hypoplastic ventricle development
and trophoblast placental defects, similar to those found in mice
lacking RXRa and PPARg. RA signaling in association with BAF180
have a critical role in controlling mesenchymal progenitor cell
differentiation into smooth muscle and ﬁbroblast lineages during
cardiac development implying an important role of BAF180 in
EPDCs.
BRG1
Mutation studies of Brg1 in different cardiac lineages showed
complex functions of Brg1 during heart development [Stankunas
et al., 2008; Hang et al., 2010]. Early deletion of Brg1 in myocardium
leads to severe cardiac defects including thin myocardium and
septum defect. These abnormalities are associated with the
myocardial proliferation defect. Knockout of Brg1 causes down‐
regulated of Bmp10 and ectopic expression of p57kip2, which
regulate proper myocardial proliferation. Rescue of Brg1 KO
phenotypes by Bmp10 suggest that Bmp10 functions at downstream
of Brg1 in myocardial proliferation. Moreover, Brg1 interacts with
HDACs and PARPs to repress a‐MHC and activate b‐MHC during
myocyte maturation during heart development. The Brg1/HDAC/
PARP is shown tomaintainb‐MHC expression. Absence of Brg1 leads
to premature differentiation of cardiomyocytes as indicated by
expression of a‐MHC. Inhibition of HDAC or PARP also causes
premature differentiation of myocytes. These ﬁndings suggest that
Brg1 control cardiac development by regulating different pathways in
proliferation and differentiation.
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Further studies have shown that a crosstalk between Brg1 and
other epigenetic factors is essential for proper function of Brg1. The
interaction of UTX and Brg1 promotes Brg1 binding to its cardiac
target genes [Lee et al., 2012]. The association of UTX and Brg1 also
signiﬁcantly promotes the interaction of Brg1 with Tbx5 which is
essential for cardiac speciﬁc function. Moreover, the recruitment of
Brg1 to cardiac enhancers are reduced in UTX knockdown. Therefore,
UTX recruits Brg1 to activate cardiac genes and proper interaction of
SWI/SNF with various epigenetic factors are important for normal
CPC differentiation.
BAF250A
The speciﬁc functions of SWI/SNF complex largely depend on its
various components. BAF250a is a critical regulatory subunit in SWI/
SNF. Our studies show that knockout of BAF250a in differentiaton
cardiac lineages displayed multiple cardiac defects [Gao et al., 2008;
Lei et al., 2012]. Single alelle deletion of BAF250a also leads to cardiac
defects, indicating that BAF250a is also required in a dosage
dependent manner. BAF250a is essential for proper differentiation of
ES cells into beating cardiomyocytes during in vitro differentiaiton.
Further analysis of the cardiac defects in BAF250a knockout embryos
suggests that BAF250a regulates both differentation and proliferation
ofmyocardium bymediating different pathways.Moreover, BAF250a
is required for efﬁcient Brg1 binding to several cardiac genes, such as
MEF2c, NKX2.5, and BMP10. DNase hypersensitivity assays have
shown that the function of SWI/SNF at cardaic targets is BAF250a
dependent. Since BAF250a and BAF180 belongs to BAF and PBAF, it
is likely that several cardiac speciﬁc SWI/SNF complexes may exist
and play important roles during CPC differentiation.
PERSPECTIVE
SWI/SNF is required in various aspects of cariogenesis and plays a
promising role in CPC differentiation. Future studies with a combined
embryonic stem cell based in vitro differentiation systems and
genetic, biochemical, and genome‐wide sequencing technologies will
enable us to fully understand SWI/SNF‐mediated epigenetic
mechanisms in guiding the proper differentiation of CPCs. We
envision that future studies will systemally reveal the following:
whether and how the dynamic regulation of SWI/SNF composition
and stoichimetry mediates CPC development; what are the key
transcription factors and epigentic factors that interact with SWI/SNF
to change cell identity during CPC differentiation; more intriguely,
how SWI/SNF primes chromatin structure at single gene, gene cluster,
topological domains, as well as nuclear compartment to faciliate gene
expression and CPC differentiation.
DYNAMICS OF SWI/SNF COMPLEX DURING CPC SPECIFICATION
AND DIFFERENTIATION
One central question of SWI/SNF in CPC differentiation is how SWI/
SNF itself is regulated. Numerous studies clearly indicate that tissue‐
speciﬁc SWI/SNFs are critical for the speciﬁcation and differentiation
of tissue‐speciﬁc progenitors [Ho and Crabtree, 2010], including
neuron and cardiac progenitors. The studies of BAF60c, BAF250a,
Brg1, and BAF180 in heart development as discussed above have
revealed a cardiac SWI/SNF (cSWI/SNF) or cSWI/SNFs in CPCs. The
existence of cSWI/SNF is also supported by the ﬁndings that certain
subunits are interchangeable and function in different cardiac cell
stages. BAF60a is shown to interact with Tbx1 in embryos tomaintain
the self‐renewal of CPCs [Chen et al., 2012]. Tbx1 regulates cardiac
progenitor proliferation and inhibit differentiation and Tbx5 is
required for cardiomyocyte differentiation. BAF60a/BAF complex
exerts a speciﬁc function in maintain self‐renewal of CPC via interact
with Tbx1. On the other hand, BAF60c interacts with Tbx5 and their
interaction is essential for the activation of cardiomyocyte structure
genes, such as Tnnt2, Myh6, and Gja1 [Takeuchi and Bruneau, 2009].
Interestingly, BAF60a is expressed in the CPCs, and poorly expressed
in cardiomyocytes, while BAF60c is highly expressed in cardiomyo-
cytes and smooth muscle cells, indicating that BAF complexes go
through a subunit change during CPC differentiation and interact
with different transcription factors to acquire cardiac speciﬁcity. In
addition, BAF45c has also been identiﬁed as a component of cSWI/
SNF [Lange et al., 2008].
Looking forward, we envision that an integrated approach in
genetics, biochemistry, and stem cell biology will yield a compre-
hensive picture of cSWI/SNF function in CPC differentiation. The
development of ESC‐based in vitro CPC systems combined with
conventional biochemical puriﬁcation techniques and state‐of‐the‐
art proteomic approach will greatly clarify the dynamic changes of
cSWI/SNF complex during CPC speciﬁcation and differentiation.
Genetic knockout studies of individual SWI/SNF subunits together
with biochemical puriﬁcation technologies will continue to provide
insight on the functions of each subunits and how that particular
subunit mediates the proper assembly and function of the whole
complex. These studies may also reveal possible auto feedback
regulations within the complex. Moreover, inducible over‐expression
of SWI/SNF components in vitro and in vivo will likely identify the
key components in cSWI/SNF that drive CPC differentiation.
INTERACTION OF SWI/SNF WITH TRANSCRIPTION FACTORS
Numerous studies have established that the interactions of SWI/SNF
with key transcription factors are essential for ES cell and organ
development. In ESCs, SWI/SNF colocalizes with Oct4, Sox2, and
Nanog in a genome‐wide manner and functionally interacts with
Oct4 and Sox2 to control the target genes for stem cell self‐renewal
and pluripotency [Ho et al., 2009]. Moreover, Brg1 is shown to
promote oligodendrocyte lineage progression and maturation [Yu
et al., 2013]. During this process, the interaction of Olig2 with Brg1
pre‐patterned the recruitment of Brg1 to oligodendrocyte enhancers.
During heart development, SWI/SNF also interacts with GATA4 and
TBX5 to promote cardiac differentiation [Lickert et al., 2004]. A
detailed genome‐wide co‐occupancy analysis of cardiac transcription
factors with SWI/SNF complex in different cardiac lineages will help
identify novel key transcription factors associated with SWI/SNF and
may also help characterize heart‐speciﬁc enhancers and reveal the
transcription cascade during CPC differentiation. In addition,
biochemical and proteomic studies could also provide information
of SWI/SNF partners during development (Fig. 3A).
SYNERGY BETWEEN SWI/SNF AND OTHER EPIGENETIC FACTORS
A synergistic interplay between SWI/SNF and numerous other
epigenetic factors are also found essential for development. Brg1 has
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been shown to interact with HDACs to direct myocardiummaturation
[Hang et al., 2010]. Brg1 coupled with histone modifying enzymes
also controls expression of critical regulators for oligodendrocyte and
muscle differentiation [Dacwag et al., 2007; Yu et al., 2013]. BAF45c
could regulate binding of acetylated histone to regulate heart
development [Zeng et al., 2010]. Moreover, SWI/SNF antagonizes the
role of polycomb groups in many development events. These results
suggest that SWI/SNF and related epigenetic factors may form
comprehensive networks during development (Fig. 3A). Genome‐
wide analysis of chromatin modiﬁcations with large‐scale protein‐
protein interaction and co‐occupancy studies of SWI/SNF and other
epigenetic factors in CPC systems developed in vitro will likely
identify an integrated chromatin modifying complex network
guiding the proper CPC differentiation.
A POSSIBLE PRIMING ROLE OF SWI/SNF FOR CPC DIFFERENTIATION
One intriguing question is whether SWI/SNF plays a priming role to
facilitate CPC differentiation. It has been shown that epigentic
modiﬁcations at chromatin can prime the target genes for
expressions. These genes are primed at a “poised” status–silent but
will be turned on immediately upon receiving signal for lineage
committment. The most prominent modiﬁcations are the concurrent
presence of H3K4me3 and H3K27me3 at gene promoters and
enhancers, termed bivalent domains. In ESCs, many poised genes
encode key factors for lineage differentiation [Mikkelsen et al., 2007].
These genes are also marked by Brg1 and low nucleosomal density
[Rada‐Iglesias et al., 2011].
During CPC differentiation, from ES cells to mesodermal cells, then
to cardiac progenitor cells (CPCs), and ﬁnally to cardiomyocytes,
there are unique epigenetic signatures in different stages. miRNA,
lncRNA, and histone modiﬁcations coordinate with speciﬁc gene
expression at different cell types [Paige et al., 2012; Wamstad
et al., 2012]. These studies indicate that the epigenetic proﬁles deﬁne
the distant enhancer elements that is required for cardiac develop-
ment. Moreover, the pattern of histone modiﬁcation and CTCF‐
binding at enhancer elements are highly associated with cell type
speciﬁc gene expression [Heintzman et al., 2009].
In addition to histone modiﬁcations, nucleosome positioning are
shown to associated with active and inactive genes [Schones
et al., 2008]. Several studies have suggested that SWI/SNF mediated
nucleosome remodeling have a priming role in specifying gene
expression during development. For example, nucleosome‐depleted
regions at transcription start site and transcription termination sites
are associated with active genes [Li et al., 2012; Hu et al., 2013]. H2A.
Z is more abundant in active gene in various organisms. During
mouse ES cell differentiation, H2A.Z regulates gene expression by
Fig. 3. Potential synergistic functions of SWI/SNF with transcription factors (TFs) and epigenetic factors (EpiFs) during CPC differentiation. A: SWI/SNF remodel
nucleosome positions and other chromatin structures to modulate DNA accessibilities, thereby regulating gene expression. B: SWI/SNF could also work with other EpiFs to
modulate higher chromatin structure in large scale to regulate long distance DNA–DNA interactions.
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mediating ‐1 nucleosome depletion. H2A.Z is essential for the
recruitment of SWI/SNF to yeast. In mammals, a recent study just
showed that SWI/SNF could be recruited by H2A.Z to deplete
nucleosome during differentiation [Li et al., 2012]. Binding of RARa
was signiﬁcantly compromized genome‐wide by H2A.Z knockdown
[Hu et al., 2013]. Our previous research imply that BAF180/PBAF
plays a role in RA signaling during heart development, [Huang
et al., 2008]. Therefore, RXRa and H2A.Z together may recruit
BAF180 and further recruit nucleosome disassembly complexes SWI/
SNF. It is possible that this preference have impact on pre‐patterning
chromatin signatures. A detailed nucleosome and histone modiﬁca-
tion mapping in both wild type and SWI/SNF knockout cells
combined with gene expression study at different cardiac lineages
will deﬁnewhether SWI/SNFmediated nucleosome remodeling play a
key priming role for CPC differentiation (Fig. 3A).
Not only nucleosome positioning in a single gene could prime its
expression, large chromatin domains could also have an impact on
gene expression. SWI/SNF were found to co‐localize with CTCF and
lamin B at many long‐distance DNA–DNA interaction regions
[Euskirchen et al., 2011]. Several higher order structures are reported
recently including topological domains [Dixon et al., 2012], A and B
compartments [Ryba et al., 2010], lamina‐associated domains (LADs)
[Peric‐Hupkes et al., 2010], replication time zones [Hiratani
et al., 2010], and large organized chromatin K9 modiﬁcation
(LOCK) domains [Wen et al., 2009]. Boundaries of topological
domains are enriched for the insulator binding protein CTCF and
LADs are related with lamin B. The big question to address next is
whether SWI/SNF contributes to form or break these structures.
SHPRH is a member of the SWI/SNF family of ATPases/helicases,
SHPRH contains the PHD (Plant HomeoDomain) domain that can
interact with dimethylated histone H3 at K9 (H3K9Me2) in vitro,
implying that SWI/SNF maybe able to break the LOCK domains.
However, the relationship of higher order chromatin structures and
their regulation are poorly deﬁned at the moment. A detailed analysis
of higher order chromatin structure changes in SWI/SNF mutants
along with the studies of the function and regulation of higher order
chromatin structures will further advance our knowledge of SWI/SNF
in epigenetic regulation during CPC differentiation (Fig. 3B).
Detailed analyses of SWI/SNF complexes during mammalian
development will establish a series of integrated and dynamic
chromatin‐ and histone‐modifying events and transcription net-
works for proper CPC differentiation. These studies may also provide
important clues in heart tissue de‐differentiation or directed
reprogramming of one mature cell type into another in the heart.
Knowledge gained from future studies of SWI/SNF in CPC
differentiation may provide novel targets to help develop
small molecules, gene therapy, and cell based therapies for heart
disease.
ACKNOWLEDGMENTS
We thank themembers of theWang laboratory for helpful discussions
of the manuscript. Z. W. is supported by the US National Institutes
of Health grant R01 HL109054‐01 and M. H. S. is supported by the
Stem Cell and Regenerative Medicine Consortium at the University of
Hong Kong.
REFERENCES
Beltrami AP, Barlucchi L, Torella D, Baker M, Limana F, Chimenti S, Kasahara
H, Rota M, Musso E, Urbanek K, Leri A, Kajstura J, Nadal‐Ginard B, Anversa P.
2003. Adult cardiac stem cells are multipotent and support myocardial
regeneration. Cell 114:763–776.
Black BL. 2007. Transcriptional pathways in second heart ﬁeld development.
Semin Cell Dev Biol 18:67–76.
Blin G, Nury D, Stefanovic S, Neri T, Guillevic O, Brinon B, Bellamy V, Rucker‐
Martin C, Barbry P, Bel A, Bruneval P, Cowan C, Pouly J, Mitalipov S, Gouadon
E, Binder P, Hagege A, Desnos M, Renaud JF, Menasche P, Puceat M. 2010. A
puriﬁed population of multipotent cardiovascular progenitors derived from
primate pluripotent stem cells engrafts in postmyocardial infarcted nonhuman
primates. J Clin Invest 120:1125–1139.
Bruneau BG. 2008. The developmental genetics of congenital heart disease.
Nature 451:943–948.
Bu L, Jiang X, Martin‐Puig S, Caron L, Zhu S, Shao Y, Roberts DJ, Huang PL,
Domian IJ, Chien KR. 2009. Human ISL1 heart progenitors generate diverse
multipotent cardiovascular cell lineages. Nature 460:113–117.
Cai CL, LiangX, Shi Y, Chu PH, Pfaff SL, Chen J, Evans S. 2003. Isl1 identiﬁes a
cardiac progenitor population that proliferates prior to differentiation and
contributes a majority of cells to the heart. Dev Cell 5:877–889.
Cairns BR, Lorch Y, Li Y, Zhang M, Lacomis L, Erdjument‐Bromage H, Tempst
P, Du J, Laurent B, Kornberg RD. 1996. RSC, an essential, abundant chromatin‐
remodeling complex. Cell 87:1249–1260.
Chen L, Fulcoli FG, Ferrentino R, Martucciello S, Illingworth EA, Baldini A.
2012. Transcriptional control in cardiac progenitors: Tbx1 interacts with the
BAF chromatin remodeling complex and regulates Wnt5a. PLoS Genet 8:
e1002571.
Christoforou N, Oskouei BN, Esteso P, Hill CM, Zimmet JM, Bian W, Bursac N,
Leong KW, Hare JM, Gearhart JD. 2010. Implantation of mouse embryonic
stem cell‐derived cardiac progenitor cells preserves function of infarcted
murine hearts. PLoS ONE 5:e11536.
Creyghton MP, Cheng AW, Welstead GG, Kooistra T, Carey BW, Steine
EJ, Hanna J, Lodato MA, Frampton GM, Sharp PA, Boyer LA, Young RA,
Jaenisch R. 2010. Histone H3K27ac separates active from poised enhancers
and predicts developmental state. Proc Natl Acad Sci U S A 107:21931–
21936.
Dacwag CS, Ohkawa Y, Pal S, Sif S, Imbalzano AN. 2007. The protein arginine
methyltransferase Prmt5 is required for myogenesis because it facilitates ATP‐
dependent chromatin remodeling. Mol Cell Biol 27:384–394.
de la Serna IL, Ohkawa Y, Imbalzano AN. 2006. Chromatin remodelling in
mammalian differentiation: Lessons from ATP‐dependent remodellers. Nat
Rev Genet 7:461–473.
Dixon JR, Selvaraj S, Yue F, Kim A, Li Y, Shen Y, Hu M, Liu JS, Ren. B. 2012.
Topological domains in mammalian genomes identiﬁed by analysis of
chromatin interactions. Nature 485:376–380.
EuskirchenGM, Auerbach RK, Davidov E, Gianoulis TA, ZhongG, Rozowsky J,
Bhardwaj N, Gerstein MB, Snyder M. 2011. Diverse roles and interactions
of the SWI/SNF chromatin remodeling complex revealed using global
approaches. PLoS Genet 7:e1002008.
Gao X, Tate P, Hu P, Tjian R, Skarnes WC, Wang. Z. 2008. ES cell pluripotency
and germ‐layer formation require the SWI/SNF chromatin remodeling
component BAF250a. Proc Natl Acad Sci USA 105:6656–6661.
Hang CT, Yang J, Han P, Cheng HL, Shang C, Ashley E, Zhou B, Chang CP.
2010. Chromatin regulation by Brg1 underlies heart muscle development and
disease. Nature 466:62–67.
Hansson EM, Lindsay ME, Chien KR. 2009. Regeneration next: Toward heart
stem cell therapeutics. Cell stem cell 5:364–377.
Heintzman ND, Hon GC, Hawkins RD, Kheradpour P, Stark A, Harp LF, Ye Z,
Lee LK, Stuart RK, Ching CW, Ching KA, Antosiewicz‐Bourget JE, Liu H, Zhang
X, Green RD, Lobanenkov VV, Stewart R, Thomson JA, Crawford GE, Kellis M,
JOURNAL OF CELLULAR BIOCHEMISTRY SWI/SNF IN CARDIAC PROGENITORS 2443
Ren. B. 2009. Histone modiﬁcations at human enhancers reﬂect global cell‐
type‐speciﬁc gene expression. Nature 459:108–112.
Hiratani I, Ryba T, Itoh M, Rathjen J, Kulik M, Papp B, Fussner E, Bazett‐Jones
DP, Plath K, Dalton S, Rathjen PD, Gilbert DM. 2010. Genome‐wide dynamics
of replication timing revealed by in vitro models of mouse embryogenesis.
Genome Res 20:155–169.
Ho L, Crabtree GR. 2010. Chromatin remodelling during development. Nature
463:474–484.
Ho L, Ronan JL, Wu J, Staahl BT, Chen L, Kuo A, Lessard J, Nesvizhskii AI,
Ranish J, Crabtree GR. 2009. An embryonic stem cell chromatin remodeling
complex, esBAF, is essential for embryonic stem cell self‐renewal and
pluripotency. Proc Natl Acad Sci U S A 106:5181–5186.
Hu G, Cui K, Northrup D, Liu C, Wang C, Tang Q, Ge K, Levens D, Crane‐
Robinson C, Zhao. K. 2013. H2A. Z facilitates access of active and repressive
complexes to chromatin in embryonic stem cell self‐renewal and differentia-
tion. Cell Stem Cell 12:180–192.
Huang X, Gao X, Diaz‐Trelles R, Ruiz‐Lozano P, Wang. Z. 2008. Coronary
development is regulated by ATP‐dependent SWI/SNF chromatin remodeling
component BAF180. Dev Biol 319:258–266.
Jessup M, Brozena S. 2003. Heart failure. N Engl J Med 348:2007–2018.
Kattman SJ, Huber TL, Keller GM. 2006. Multipotent ﬂk‐1þ cardiovascular
progenitor cells give rise to the cardiomyocyte, endothelial, and vascular
smooth muscle lineages. Dev Cell 11:723–732.
Keegan BR, Feldman JL, Begemann G, Ingham PW, Yelon D. 2005. Retinoic
acid signaling restricts the cardiac progenitor pool. Science 307:247–249.
Kingston RE, Tamkun JW. 2007. Transcriptional regulation by Trithorax group
proteins. In: Allis CD, Jenuwein T, Reinberg D, editors. Epgenetics. New York:
Cold Spring Harbor Laboratory Press. 231–248.
Kwon C, Qian L, Cheng P, Nigam V, Arnold J, Srivastava D. 2009. A regulatory
pathway involving Notch1/beta‐catenin/Isl1 determines cardiac progenitor
cell fate. Nat Cell Biol 11:951–957.
Lange M, Kaynak B, Forster UB, Tönjes M, Fischer JJ, Grimm C, Schlesinger J,
Just S, Dunkel I, Krueger T,Mebus S, LehrachH, Lurz R, Gobom J, RottbauerW,
Abdelilah‐Seyfried S, Sperling S. 2008. Regulation of muscle development by
DPF3, a novel histone acetylation and methylation reader of the BAF
chromatin remodeling complex. Genes Dev 22:2370–2384.
Lee S, Lee JW, Lee. SK. 2012. UTX, a histone H3‐lysine 27 demethylase, acts as
a critical switch to activate the cardiac developmental program. Dev Cell
22:25–37.
Lei I, Gao X, ShamMH,Wang. Z. 2012. SWI/SNF Protein component BAF250a
regulates cardiac progenitor cell differentiation by modulating chromatin
accessibility during second heart ﬁeld. J Biol Chem 287:24255–24262.
Lessard J,Wu JI, Ranish JA,WanM,WinslowMM, Staahl BT,WuH, Aebersold
R, Graef IA, Crabtree GR. 2007. An essential switch in subunit composition of a
chromatin remodeling complex during neural development. Neuron 55:201–
215.
Li Z, Gadue P, Chen K, Jiao Y, Tuteja G, Schug J, Li W, Kaestner KH. 2012.
Foxa2 and H2A.Z. mediate nucleosome depletion during embryonic stem cell
differentiation. Cell 151:1608–1616.
Lickert H, Takeuchi JK, Von Both I, Walls JR, McAuliffe F, Adamson SL,
Henkelman RM, Wrana JL, Rossant J, Bruneau BG. 2004. Baf60c is essential
for function of BAF chromatin remodelling complexes in heart development.
Nature 432:107–112.
Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. 2006. Global and
regional burden of disease and risk factors, 2001: Systematic analysis of
population health data. Lancet 367:1747–1757.
Lorch Y, Zhang M, Kornberg RD. 1999. Histone octamer transfer by a
chromatin‐remodeling complex. Cell 96:389–392.
Lou X, Deshwar AR, Crump JG, Scott IC. 2011. Smarcd3b and Gata5 promote a
cardiac progenitor fate in the zebraﬁsh embryo. Development 138:3113–3123.
Martin‐Puig S, Wang Z, Chien KR. 2008. Lives of a heart cell: Tracing the
origins of cardiac progenitors. Cell stem cell 2:320–331.
Mikkelsen TS, Ku M, Jaffe DB, Issac B, Lieberman E, Giannoukos G, Alvarez P,
Brockman W, Kim TK, Koche RP, Lee W, Mendenhall E, Oapos Donovan A,
Presser A, Russ C, Xie X, Meissner A, Wernig M, Jaenisch R, Nusbaum C,
Lander ES, Bernstein, BE. 2007. Genome‐wide maps of chromatin state in
pluripotent and lineage‐committed cells. Nature 448:553–560.
Moretti A, Caron L, Nakano A, Lam JT, Bernshausen A, Chen Y, Qyang Y, Bu L,
Sasaki M, Martin‐Puig S, Sun Y, Evans SM, Laugwitz KL, Chien KR. 2006.
Multipotent embryonic isl1þ progenitor cells lead to cardiac, smooth muscle,
and endothelial cell diversiﬁcation. Cell 127:1151–1165.
Nie Z, Xue Y, Yang D, Zhou S, Deroo BJ, Archer TK, Wang. W. 2000. A
speciﬁcity and targeting subunit of a human SWI/SNF family‐related
chromatin‐remodeling complex. Mol Cell Biol 20:8879–8888.
Oh H, Bradfute SB, Gallardo TD, Nakamura T, Gaussin V, Mishina Y, Pocius J,
Michael LH, Behringer RR, Garry DJ, EntmanML, SchneiderMD. 2003. Cardiac
progenitor cells from adult myocardium: Homing, differentiation, and fusion
after infarction. Proc Natl Acad Sci USA 100:12313–12318.
Olson EN. 2006. Gene regulatory networks in the evolution and development
of the heart. Science 313:1922–1927.
Paige SL, Thomas S, Stoick‐Cooper CL, Wang H, Maves L, Sandstrom R, Pabon
L, Reinecke H, Pratt G, Keller G, Moon RT, Stamatoyannopoulos J, Murry CE.
2012. A temporal chromatin signature in human embryonic stem cells
identiﬁes regulators of cardiac development. Cell 151:221–232.
Peric‐Hupkes D, Meuleman W, Pagie L, Bruggeman SW, Solovei I, Brugman
W, Graf S, Flicek P, Kerkhoven RM, van Lohuizen M, Reinders M, Wessels L,
van Steensel B. 2010. Molecular maps of the reorganization of genome‐
nuclear lamina interactions during differentiation. Mol Cell 38:603–613.
Rada‐Iglesias A, Bajpai R, Swigut T, Brugmann SA, Flynn RA, Wysocka J.
2011. A unique chromatin signature uncovers early developmental enhancers
in humans. Nature 470:279–283.
Ryba T, Hiratani I, Lu J, ItohM, KulikM, Zhang J, Schulz TC, Robins AJ, Dalton
S, Gilbert DM. 2010. Evolutionarily conserved replication timing proﬁles
predict long‐range chromatin interactions and distinguish closely related cell
types. Genome Res 20:761–770.
Schones DE, Cui K, Cuddapah S, Roh TY, Barski A, Wang Z, Wei G, Zhao. K.
2008. Dynamic regulation of nucleosome positioning in the human genome.
Cell 132:887–898.
Srivastava D. 2006. Making or breaking the heart: From lineage determination
to morphogenesis. Cell 126:1037–1048.
Stankunas K, Hang CT, Tsun ZY, Chen H, Lee NV, Wu JI, Shang C, Bayle JH,
Shou W, Iruela‐Arispe ML, Chang CP. 2008. Endocardial Brg1 represses
ADAMTS1 to maintain the microenvironment for myocardial morphogenesis.
Dev Cell 14:298–311.
Stevens KN, Hakonarson H, Kim CE, Doevendans PA, Koeleman BP, Mital S,
Raue J, Glessner JT, Coles JG, Moreno V, Granger A, Gruber SB, Gruber PJ.
2010. Common variation in ISL1 confers genetic susceptibility for human
congenital heart disease. PLoS ONE 5:e10855.
Suzuki MM, Bird. A. 2008. DNAmethylation landscapes: Provocative insights
from epigenomics. Nat Rev Genet 9:465–476.
Takeuchi JK, Bruneau BG. 2009. Directed transdifferentiation of mouse
mesoderm to heart tissue by deﬁned factors. Nature 459:708–711.
Wamstad JA, Alexander JM, Truty RM, Shrikumar A, Li F, Eilertson KE, Ding
H,Wylie JN, Pico AR, Capra JA, Erwin G, Kattman SJ, Keller GM, Srivastava D,
Levine SS, Pollard KS, Holloway AK, Boyer LA, Bruneau BG. 2012. Dynamic
and coordinated epigenetic regulation of developmental transitions in the
cardiac lineage. Cell 151:206–220.
Wang W, Côté J, Xue Y, Zhou S, Khavari PA, Biggar SR, Muchardt C, Kalpana
GV, Goff SP, Yaniv M, Workman JL, Crabtree GR. 1996. Puriﬁcation and
biochemical heterogeneity of the mammalian SWI‐SNF complex. Embo J
15:5370–5382.
2444 SWI/SNF IN CARDIAC PROGENITORS JOURNAL OF CELLULAR BIOCHEMISTRY
Wang Z, Zhai W, Richardson JA, Olson EN, Meneses JJ, Firpo MT, Kang C,
Skarnes WC, Tjian R. 2004. Polybromo protein BAF180 functions in
mammalian cardiac chamber maturation. Genes Dev 18:3106–3116.
Wen B, Wu H, Shinkai Y, Irizarry RA, Feinberg AP. 2009. Large histone H3
lysine 9 dimethylated chromatin blocks distinguish differentiated from
embryonic stem cells. Nat Genet 41:246–250.
Whitehouse I, Flaus A, Cairns BR, White MF, Workman JL, Owen‐Hughes T.
1999. Nucleosome mobilization catalysed by the yeast SWI/SNF complex.
Nature 400:784–787.
Wu SM, Fujiwara Y, Cibulsky SM, ClaphamDE, Lien CL, Schultheiss TM, Orkin
SH. 2006. Developmental origin of a bipotential myocardial and smooth
muscle cell precursor in the mammalian heart. Cell 127:1137–1150.
Wu SM, Chien KR, Mummery C. 2008. Origins and fates of cardiovascular
progenitor cells. Cell 132:537–543.
Wu JI, Lessard J, Crabtree GR. 2009. Understanding the words of chromatin
regulation. Cell 136:200–206.
Xue Y, Canman JC, Lee CS, Nie Z, Yang D, Moreno GT, YoungMK, Salmon ED,
Wang. W. 2000. The human SWI/SNF‐B chromatin‐remodeling complex is
related to yeast rsc and localizes at kinetochores of mitotic chromosomes. Proc
Natl Acad Sci U S A 97:13015–13020.
Yan Z, Cui K, Murray DM, Ling C, Xue Y, Gerstein A, Parsons R, Zhao K,Wang.
W. 2005. PBAF chromatin‐remodeling complex requires a novel speciﬁcity
subunit, BAF200, to regulate expression of selective interferon‐responsive
genes. Genes Dev 19:1662–1667.
Yan Z,Wang Z, Sharova L, SharovAA, Ling C, Piao Y, Aiba K,MatobaR,Wang
W, Ko MSH. 2008. The BAF250b‐associated SWI/SNF chromatin‐remodeling
complex is required for the maintenance of undifferentiated mouse embryonic
stem cells. Stem Cells 26:1155–1165.
Yang L, Soonpaa MH, Adler ED, Roepke TK, Kattman SJ, Kennedy M,
Henckaerts E, Bonham K, Abbott GW, Linden RM, Field LJ, Keller GM. 2008.
Human cardiovascular progenitor cells develop from a KDRþ embryonic‐
stem‐cell‐derived population. Nature 453:524–528.
Yu Y, Chen Y, Kim B, Wang H, Zhao C, He X, Liu L, Liu W, Wu LM, Mao M,
Chan JR, Wu J, Lu. QR. 2013. Olig2 targets chromatin remodelers to enhancers
to initiate oligodendrocyte differentiation. Cell 152:248–261.
Zaidi SK, YoungDW,MontecinoM, vanWijnenAJ, Stein JL, Lian JB, SteinGS.
2011. Bookmarking the genome: Maintenance of epigenetic information. J
Biol Chem 286:18355–18361.
Zeng L, Zhang Q, Li S, Plotnikov AN, Walsh MJ, Zhou. MM. 2010. Mechanism
and regulation of acetylated histone binding by the tandem PHD ﬁnger of
DPF3b. Nature 466:258–262.
Zhou VW, Goren A, Bernstein BE. 2011. Charting histone modiﬁcations
and the functional organization of mammalian genomes. Nat Rev Genet 12:
7–18.
JOURNAL OF CELLULAR BIOCHEMISTRY SWI/SNF IN CARDIAC PROGENITORS 2445
